Connect Biopharma will present findings on Rademikibart's efficacy for asthma at EAACI 2025 in Glasgow.
Quiver AI Summary
Connect Biopharma Holdings Limited announced that it will present two studies on its drug rademikibart at the European Academy of Allergy and Clinical Immunology 2025 Annual Congress from June 13-16, 2025, in Glasgow and online. The presentations will focus on the reduction of annual exacerbations and improvement in lung function in patients with eosinophilic driven, Type 2 asthma. Rademikibart, a novel anti-interleukin-4-receptor alpha antibody, aims to improve care for asthma and chronic obstructive pulmonary disease (COPD) by addressing acute exacerbations that affect millions of patients in the U.S. The company reported positive results from Phase 2 trials, showing significant efficacy and safety, with improvements in lung function measurable within days. Presentations will be accessible on Connect's website post-event.
Potential Positives
- Connect Biopharma is presenting significant clinical data at a major scientific congress (EAACI 2025), enhancing its visibility in the biopharmaceutical industry.
- The presentations highlight the promising efficacy and safety of rademikibart, a potential best-in-class treatment for asthma and COPD, addressing a significant unmet medical need.
- Positive Phase 2 trial results demonstrate rapid improvements in lung function and reduced exacerbations, which could attract further investment and interest in the company's pipeline.
- Rademikibart's initial focus on acute exacerbations may lead to chronic utilization, representing a substantial market opportunity in both asthma and COPD treatment spaces.
Potential Negatives
- None
FAQ
What is Connect Biopharma's main focus?
Connect Biopharma focuses on transforming acute and chronic care for asthma and COPD.
When is the EAACI 2025 Annual Congress?
The EAACI 2025 Annual Congress will take place from June 13-16, 2025.
Who will present at the EAACI congress?
Dr. Rekha Chaudhuri will present at the congress on Rademikibart's efficacy for asthma.
What is Rademikibart?
Rademikibart is a next-generation anti-interleukin-4-receptor alpha antibody for treating asthma and COPD.
Where can I find the presentations after the congress?
All presentations will be available on Connect Biopharma's website under the presentations and publications section.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CNTB Hedge Fund Activity
We have seen 2 institutional investors add shares of $CNTB stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) removed 241,755 shares (-47.3%) from their portfolio in Q1 2025, for an estimated $132,965
- CATALINA CAPITAL GROUP, LLC removed 47,867 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $26,326
- ROYAL BANK OF CANADA removed 40,000 shares (-49.8%) from their portfolio in Q1 2025, for an estimated $22,000
- KEUDELL/MORRISON WEALTH MANAGEMENT removed 33,450 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $46,161
- RENAISSANCE TECHNOLOGIES LLC removed 19,897 shares (-14.8%) from their portfolio in Q1 2025, for an estimated $10,943
- GEOWEALTH MANAGEMENT, LLC removed 10,942 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $6,018
- ADAR1 CAPITAL MANAGEMENT, LLC added 10,300 shares (+inf%) to their portfolio in Q1 2025, for an estimated $5,665
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually.
The presentation details are as follows:
Abstract Title:
Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma
Abstract Number:
001671
Presenter:
Rekha Chaudhuri, M.D.
Session Title:
Clinical Trials on Airways Diseases
Date and Time:
Friday, June 13
th
from 3:00 p.m. – 4:30 p.m. BST
Abstract Title:
Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma
Abstract Number:
001678
Presenter:
Rekha Chaudhuri, M.D.
Session Title:
Clinical Trials on Airways Diseases
Date and Time:
Friday, June 13
th
from 3:00 p.m. – 4:30 p.m. BST
Following the presentations, each presentation will be available on Connect’s website under the presentations and publications section .
About Connect Biopharma
and Rademikibart
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV
1
), observed within one week—and in most cases, within 24 hours via home spirometry.
For more information visit www.connectbiopharm.com .
Investor Relations Contact:
Alex Lobo
Precision AQ
[email protected]
(212) 698-8802
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
[email protected]
[email protected]
(858) 717-2310 or (646) 942-5604
